Impact of the Management and Proportion of Lost to Follow-Up Cases on Cancer Survival Estimates for Small Population-Based Cancer Registries.


Journal

Journal of cancer epidemiology
ISSN: 1687-8558
Titre abrégé: J Cancer Epidemiol
Pays: Egypt
ID NLM: 101519967

Informations de publication

Date de publication:
2022
Historique:
received: 01 10 2021
revised: 22 12 2021
accepted: 13 01 2022
entrez: 10 2 2022
pubmed: 11 2 2022
medline: 11 2 2022
Statut: epublish

Résumé

Estimation of survival requires follow-up of patients from diagnosis until death ensuring complete and good quality data. Many population-based cancer registries in low- and middle-income countries have difficulties linking registry data with regional or national vital statistics, increasing the chances of cases lost to follow-up. The impact of lost to follow-up cases on survival estimates from small population-based cancer registries (<500 cases) has been understudied, and bias could be larger than in larger registries. We simulated scenarios based on idealized real data from three population-based cancer registries to assess the impact of loss to follow-up on 1-5-year overall and net survival for stomach, colon, and thyroid cancers-cancer types with very different prognosis. Multiple scenarios with varying of lost to follow-up proportions (1-20%) and sample sizes of (100-500 cases) were carried out. We investigated the impact of excluding versus censoring lost to follow-up cases; punctual and bootstrap confidence intervals for the average bias are presented. Censoring of lost to follow-up cases lead to overestimation of the overall survival, this effect was strongest for cancers with a poor prognosis and increased with follow-up time and higher proportion of lost to follow-up cases; these effects were slightly larger for net survival than overall survival. Excluding cases lost to follow-up did not generate a bias on survival estimates on average, but in individual cases, there were under- and overestimating survival. For gastric, colon, and thyroid cancer, relative bias on 5-year cancer survival with 1% of lost to follow-up varied between 6% and 125%, 2% and 40%, and 0.1% and 1.0%, respectively. Estimation of cancer survival from small population-based registries must be interpreted with caution: even small proportions of censoring, or excluding lost to follow-up cases can inflate survival, making it hard to interpret comparison across regions or countries.

Sections du résumé

BACKGROUND BACKGROUND
Estimation of survival requires follow-up of patients from diagnosis until death ensuring complete and good quality data. Many population-based cancer registries in low- and middle-income countries have difficulties linking registry data with regional or national vital statistics, increasing the chances of cases lost to follow-up. The impact of lost to follow-up cases on survival estimates from small population-based cancer registries (<500 cases) has been understudied, and bias could be larger than in larger registries.
METHODS METHODS
We simulated scenarios based on idealized real data from three population-based cancer registries to assess the impact of loss to follow-up on 1-5-year overall and net survival for stomach, colon, and thyroid cancers-cancer types with very different prognosis. Multiple scenarios with varying of lost to follow-up proportions (1-20%) and sample sizes of (100-500 cases) were carried out. We investigated the impact of excluding versus censoring lost to follow-up cases; punctual and bootstrap confidence intervals for the average bias are presented.
RESULTS RESULTS
Censoring of lost to follow-up cases lead to overestimation of the overall survival, this effect was strongest for cancers with a poor prognosis and increased with follow-up time and higher proportion of lost to follow-up cases; these effects were slightly larger for net survival than overall survival. Excluding cases lost to follow-up did not generate a bias on survival estimates on average, but in individual cases, there were under- and overestimating survival. For gastric, colon, and thyroid cancer, relative bias on 5-year cancer survival with 1% of lost to follow-up varied between 6% and 125%, 2% and 40%, and 0.1% and 1.0%, respectively.
CONCLUSION CONCLUSIONS
Estimation of cancer survival from small population-based registries must be interpreted with caution: even small proportions of censoring, or excluding lost to follow-up cases can inflate survival, making it hard to interpret comparison across regions or countries.

Identifiants

pubmed: 35140789
doi: 10.1155/2022/9068214
pmc: PMC8818438
doi:

Types de publication

Journal Article

Langues

eng

Pagination

9068214

Informations de copyright

Copyright © 2022 Fabian Gil et al.

Déclaration de conflit d'intérêts

The authors declare that they have no competing interests.

Références

J Natl Cancer Inst Monogr. 2014 Nov;2014(49):210-7
pubmed: 25417234
Epidemiol Rev. 2017 Jan 1;39(1):161-169
pubmed: 28472440
BMJ. 2011 Jun 09;342:d3399
pubmed: 21659366
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Br J Cancer. 2011 Jun 28;105(1):170-6
pubmed: 21559016
Biometrics. 2012 Mar;68(1):113-20
pubmed: 21689081
Br J Cancer. 2013 Feb 19;108(3):691-8
pubmed: 23361055
Salud Publica Mex. 2016 Apr;58(2):309-16
pubmed: 27557391
Br J Cancer. 2021 Mar;124(5):1026-1032
pubmed: 33293692
BMJ Open. 2020 Jan 13;10(1):e033510
pubmed: 31937655
Colomb Med (Cali). 2018 Mar 30;49(1):121-127
pubmed: 29983472
Lancet. 2018 Mar 17;391(10125):1023-1075
pubmed: 29395269
Epidemiology. 2016 Jan;27(1):91-7
pubmed: 26484424
Int J Cancer. 2009 Jul 15;125(2):432-7
pubmed: 19422045
Salud Publica Mex. 2013 Aug;55(4):368-78
pubmed: 24165712
Int J Cancer. 2021 Jul 1;149(1):12-20
pubmed: 33231289
Cancer Epidemiol. 2021 Apr;71(Pt A):101881
pubmed: 33440295
Lancet Diabetes Endocrinol. 2021 Apr;9(4):225-234
pubmed: 33662333
Cancer. 2021 Aug 15;127(16):3029-3030
pubmed: 34086348
Cancer Epidemiol. 2016 Dec;45 Suppl 1:S13-S19
pubmed: 27760725
Lancet Diabetes Endocrinol. 2021 Jun;9(6):330-332
pubmed: 33891886

Auteurs

Fabian Gil (F)

PhD Program in Clinical Epidemiology, Department of Clinical Epidemiology and Biostatistics, Pontificia Universidad Javeriana, Bogotá, Colombia.
Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine, Pontificia Universidad Javeriana, Bogotá, Colombia.

Adalberto Miranda-Filho (A)

Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France.

Claudia Uribe-Perez (C)

Population Registry of Cancer of the Metropolitan Area of Bucaramanga, Genetic Study of Complex Diseases Research Group, Universidad Autónoma de Bucaramanga, Bucaramanga, Colombia.

N E Arias-Ortiz (NE)

Population Registry of Cancer of Manizales, Health Promotion and Disease Prevention Research Group (Grupo de Investigación Promoción de la Salud y Prevención de la Enfermedad-GIPSPE) Universidad de Caldas, Manizales, Colombia.

M C Yépez-Chamorro (MC)

Cancer Registry of Pasto, Centro de Estudios en Salud (CESUN), Facultad de Ciencias de la Salud, Universidad de Nariño, Colombia.

L M Bravo (LM)

Cancer Registry of Pasto, Centro de Estudios en Salud (CESUN), Universidad de Nariño, Colombia.

Esther de Vries (E)

Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine, Pontificia Universidad Javeriana, Bogotá, Colombia.

Classifications MeSH